The real cost of theoretic risk avoidance: The need to challenge unsubstantiated concerns about131I therapy

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 681-682

  Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

EUROPE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; LUNG METASTASIS; LYMPH NODE METASTASIS; PATIENT CARE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION EXPOSURE; RADIOISOTOPE THERAPY; REVIEW; RISK ASSESSMENT; THYROID CARCINOMA;

HUMANS; IODINE RADIOISOTOPES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RISK ASSESSMENT; THYROID NEOPLASMS;

EID: 79955755631     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081927     Document Type: Review

References (5)

1. Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy resulted in a poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683-689.
2. 131I) therapy for thyroid carcinoma. JAMA. 2000;283:2272-2274.
3. 131I. Radiat Prot Dosimetry. 2006;118:22-27.
4. Fisher D, Gilley D, Langhorst S, et al. Advisory Committee on the Medical Use of Isotopes (ACMUI): Patient Release Report - December 13, 2010 Available at: http://adamswebsearch2.nrc. gov/idmws/DocContent.dll?library=PU-ADAMS^ pbntad01&LogonID=a04e47b69c822268ae178 6d773f963c4&id=103490039. Accessed March 7, 2011.
5. Kloos RT. Survey of radioiodine therapy safety practices highlights the need for user-friendly recommendations. Thyroid. 2011;21:97-99.